ASIA-PACIFIC BOTULINUM TOXIN MARKET 2021-2028

 

 

TABLE OF CONTENTS

 

1.     ASIA-PACIFIC BOTULINUM TOXIN MARKET – SUMMARY     

2.     INDUSTRY OUTLOOK

1.1. KEY INSIGHTS     

1.1.1.    SURGE IN DISPOSABLE INCOME       

1.1.2.    GROWING NUMBER OF MEN OPTING FOR COSMETIC TREATMENT  

1.1.3.    DEVELOPMENT OF HEALTHCARE INFRASTRUCTURE    

1.1. IMPACT OF COVID-19 ON THE BOTULINUM TOXIN INDUSTRY 

1.2. PORTER’S FIVE FORCES ANALYSIS 

1.1.1.    THREAT OF NEW ENTRANTS   

1.1.2.    THREAT OF SUBSTITUTE         

1.1.3.    BARGAINING POWER OF SUPPLIERS

1.1.4.    BARGAINING POWER OF BUYERS     

1.1.5.    THREAT OF COMPETITIVE RIVALRY  

1.1. MARKET ATTRACTIVENESS MATRIX

1.2. VENDOR SCORECARD  

1.3. KEY MARKET STRATEGIES     

1.1.1.    NEW PRODUCT LAUNCHES     

1.1. MARKET DRIVERS         

1.1.1.    INCREASING DEMAND FOR AESTHETIC PROCEDURES 

1.1.2.    EXPANSION OF BOTULINUM TOXIN INTO THERAPEUTIC APPLICATIONS        

1.1. MARKET RESTRAINTS   

1.1.1.    ADVERSE EFFECTS ASSOCIATED WITH BOTULINUM TOXIN  

1.1.2.    LACK OF REIMBURSEMENT POLICIES SUPPORTING COSMETIC PROCEDURES 

1.1.3.    LACK OF INTERCHANGEABILITY BETWEEN BOTULINUM TOXIN PRODUCTS   

1.1. MARKET OPPORTUNITIES      

1.1.1.    INCREASING AGING POPULATION    

1.1.2.    RISE IN MEDICAL TOURISM     

1.     ASIA-PACIFIC BOTULINUM TOXIN MARKET – BY TYPE        

1.1. TYPE A      

1.2. TYPE B      

2.     ASIA-PACIFIC BOTULINUM TOXIN MARKET – BY APPLICATION     

1.1. COSMETIC APPLICATIONS      

1.1.1.    GLABELLAR LINES         

1.1.2.    LATERAL CANTHAL LINES (CROW’S FEET) 

1.1.3.    FOREHEAD LINES

1.1.4.    OTHER COSMETIC APPLICATIONS    

1.1. NON-COSMETIC APPLICATIONS       

1.1.1.    DYSTONIA  

1.1.2.    CHRONIC MIGRAINE      

1.1.3.    OPHTHALMOLOGIC DISORDERS       

1.1.4.    OTHER NON-COSMETIC APPLICATIONS     

2.     ASIA-PACIFIC BOTULINUM TOXIN MARKET – BY END-USER

1.1. HOSPITALS

1.2. CLINICS AND OTHERS  

2.     ASIA-PACIFIC BOTULINUM TOXIN MARKET – REGIONAL OUTLOOK              

1.1. COUNTRY ANALYSIS     

1.1.1.    CHINA         

1.1.2.    JAPAN         

1.1.3.    INDIA

1.1.4.    SOUTH KOREA     

1.1.5.    ASEAN COUNTRIES        

1.1.6.    AUSTRALIA & NEW ZEALAND   

1.1.7.    REST OF ASIA-PACIFIC  

1.     COMPETITIVE LANDSCAPE 

1.1. ABBVIE INC

1.2. EVOLUS INC

1.3. GALDERMA PHARMA SA (ACQUIRED BY EQT)     

1.4. HUGEL INC

1.5. IPSEN PHARMA   

1.6. MERZ PHARMA    

1.7. MEDYTOX INC

1.8. REVANCE THERAPEUTICS INC

1.9. US WORLDMEDS LLC    

1.     METHODOLOGY & SCOPE  

1.1. RESEARCH SCOPE & DELIVERABLES        

1.2. SOURCES OF DATA      

1.3. RESEARCH METHODOLOGY

 

 

LIST OF TABLES

 

TABLE 1: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)

TABLE 2: MARKET ATTRACTIVENESS MATRIX

TABLE 3: VENDOR SCORECARD

TABLE 4: LIST OF NEW PRODUCT LAUNCHES

TABLE 5: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY TYPE, 2021-2028 (IN $ MILLION)

TABLE 6: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2028 (IN $ MILLION)

TABLE 7: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY COSMETIC APPLICATIONS, 2021-2028 (IN $ MILLION)

TABLE 8: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY NON-COSMETIC APPLICATIONS, 2021-2028 (IN $ MILLION)

TABLE 9: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY END-USER, 2021-2028 (IN $ MILLION)

TABLE 10: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY REGIONAL OUTLOOK, 2021-2028 (IN $ MILLION)

TABLE 11: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)

 

 

LIST OF FIGURES

 

FIGURE 1: PORTER’S FIVE FORCES ANALYSIS

FIGURE 2: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY TYPE, 2020 & 2028

FIGURE 3: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY TYPE A, 2021-2028 (IN $ MILLION)

FIGURE 4: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY TYPE B, 2021-2028 (IN $ MILLION)

FIGURE 5: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY APPLICATION, 2020 & 2028

FIGURE 6: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY COSMETIC APPLICATIONS, 2021-2028 (IN $ MILLION)

FIGURE 7: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY GLABELLAR LINES, 2021-2028 (IN $ MILLION)

FIGURE 8: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY LATERAL CANTHAL LINES (CROW’S FEET), 2021-2028 (IN $ MILLION)

FIGURE 9: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY FOREHEAD LINES, 2021-2028 (IN $ MILLION)

FIGURE 10: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY OTHER COSMETIC APPLICATIONS, 2021-2028 (IN $ MILLION)

FIGURE 11: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY NON-COSMETIC APPLICATIONS, 2021-2028 (IN $ MILLION)

FIGURE 12: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY DYSTONIA, 2021-2028 (IN $ MILLION)

FIGURE 13: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY CHRONIC MIGRAINE, 2021-2028 (IN $ MILLION)

FIGURE 14: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY OPHTHALMOLOGIC DISORDERS, 2021-2028 (IN $ MILLION)

FIGURE 15: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY OTHER NON-COSMETIC APPLICATIONS, 2021-2028 (IN $ MILLION)

FIGURE 16: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY END-USER, 2020 & 2028

FIGURE 17: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY HOSPITALS, 2021-2028 (IN $ MILLION)

FIGURE 18: ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY CLINICS AND OTHERS, 2021-2028 (IN $ MILLION)

FIGURE 19: ASIA-PACIFIC BOTULINUM TOXIN MARKET, REGIONAL OUTLOOK, 2020 & 2028 (IN %)

FIGURE 20: CHINA BOTULINUM TOXIN MARKET 2021-2028 (IN $ MILLION)

FIGURE 21: JAPAN BOTULINUM TOXIN MARKET 2021-2028 (IN $ MILLION)

FIGURE 22: INDIA BOTULINUM TOXIN MARKET 2021-2028 (IN $ MILLION)

FIGURE 23: SOUTH KOREA BOTULINUM TOXIN MARKET 2021-2028 (IN $ MILLION)

FIGURE 24: ASEAN COUNTRIES BOTULINUM TOXIN MARKET 2021-2028 (IN $ MILLION)

FIGURE 25: AUSTRALIA & NEW ZEALAND BOTULINUM TOXIN MARKET 2021-2028 (IN $ MILLION)

FIGURE 26: REST OF ASIA-PACIFIC BOTULINUM TOXIN MARKET 2021-2028 (IN $ MILLION)

 

 

MARKET OUTLOOK

 

A Triton Market Research report states that the botulinum toxin market in the Asia-Pacific is likely to grow with a CAGR of 6.24% in terms of revenue during the forecast period from 2021 to 2028. China, Japan, India, South Korea, Australia & New Zealand, ASEAN countries, and Rest of APAC together form the market in this region.

A study published in the Journal of Headache and Pain put forth that, in 2017, the average prevalence rate of migraine in South Korea was nearly 7%, considering people in the age group of 40-49 years. It further stated that, only 24.4% of the individuals having migraine consulted a physician for this issue. Close to 64.3% of the people were taking medication to treat headache, and among those, close to 93% of the people were taking over-the-counter drugs. The rising number of people being affected by migraine has thus increased the demand for botulinum toxin for chronic migraine in South Korea.

A few organizations in the country are involved in activities to support the people suffering from migraine. The Korean Headache Society is one such organization that continuously keeps track of new drugs entering the market, in order to help people across the nation deal with this condition. Apart from this, the demand for botulinum toxin for cosmetic purposes from Korean people is very high. Besides, South Korea is also one of the major exporters of botulinum toxin, worldwide. All these factors are contributing to the growth of the studied market in South Korea in the coming years.

 

 

COMPETITIVE OUTLOOK

 

The companies that have been mentioned in the botulinum toxin market report are Abbvie Inc (Allergan Plc), Revance Therapeutics Inc, Evolus Inc, Ipsen Pharma, and US WorldMeds LLC.

 

Get more insights into the Asia-Pacific Botulinum Toxin Market:

 

https://www.tritonmarketresearch.com/reports/asia-pacific-botulinum-toxin-market

 

 

 

SEGMENTATION

 

1.     ABBVIE INC     

2.     EVOLUS INC

3.     GALDERMA PHARMA SA (ACQUIRED BY EQT) 

4.     HUGEL INC

5.     IPSEN PHARMA         

6.     MERZ PHARMA

7.     MEDYTOX INC

8.     REVANCE THERAPEUTICS INC

9.     US WORLDMEDS LLC